Antibody Drug Conjugates Market to Reach USD 18.1 Bn to 2022, States RNCOS in Its New Report Published at MarketPublishers.com
27 Feb 2017 • by Natalie Aster
LONDON – Antibody drug conjugates (ADCs) incorporate the exclusive targeting property of monoclonal antibodies (mAbs) with the tumour cell killing ability of cytotoxic medicines. This enables discrimination between healthy and invaded tissues. Advances in coupling mAbs to cytotoxic medicines allow better control of the pharmacokinetics of drugs, and considerably enhance delivery to target specific human tissues. Powerful novel oncology drugs can currently be utilised to target cancers, whilst minimising the exposure of healthy tissues. The potential for novel therapeutic innovations in the industry is limelighted by the recent approval of two potent ADCs - Adcetris and Kadcyla, followed by a range of ADCs in pipeline.
The ADC market size is estimated to amount to USD 18.1 billion by 2022. The ADCs are likely to show their full market potential soon in the offing.
New research report “Global Antibody Drug Conjugates Market By Drug, Pipeline Analysis Outlook 2022” created by RNCOS E-Services offers a detailed analysis of the marketplace. It gives unbiased information on ADCs at different clinical trial phases, with a specific focus on Adcetris and Kadcyla. The report provides a granular analysis of ADCs of firms and research organisations, segmented based on clinical phase, indications for which they are being developed, MoA, form of linker, drug products, and technology. The report provides all-encompassing examination of different ADCs in early and advanced phases of development. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry’s growth.
Furthermore, the publication offers a discussion of selected key players active in the ADC marketplace comprising a brief overview of business activities of each company in tandem with their pipeline and product portfolios, recent developments, as well as comparative study of their weak points and strengths.
More new reports by RNCOS are available in this Market Publishers’ catalogue.